MD Anderson, Sibylla Biotech collaborate to develop small-molecule protein degraders

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer.

August 14, 2026

Vol.52 No.32

By Richard L. Schilsky, H. Kim Lyerly, Thomas R. Fleming and Renzo Canetta

Podcast

Pour a Scotch, we’re talking clinical trials and prediction markets

In last week’s issue of The Cancer Letter, the cover story featured coverage of Kalshi, an online prediction market exchange, launching a pilot program in which one can place bets on both outcomes of trials and FDA decisions.

August 05, 2026

Vol.52 No.31

Cancer Policy

House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role

At a recent House Energy and Commerce Health Subcommittee hearing titled “Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role in Advancing U.S. Drug Development,” lawmakers examined ways to increase efficiency and speed across early-stage clinical trial development.

July 17, 2026

Vol.52 No.28

By Claire Marie Porter

Cancer Policy

FDA halts public release of Complete Response Letters, following citizen petition

FDA will temporarily stop publicly releasing rejection letters as it evaluates potential response to a citizen petition issued by an unnamed pharmaceutical company challenging the legality of the practice.

July 10, 2026

Vol.52 No.27

By Claire Marie Porter

Obituary

Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61

Maura L. Gillison, MD, PhD, a medical oncologist and molecular epidemiologist whose work changed the standard of care for head and neck cancer by distinguishing human papillomavirus-positive from HPV-negative disease and thereby guiding diagnosis, treatment and prevention, died on June 21.

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

Project Purple has awarded a $375,000 Research Recovery Grant to researchers at the University of Texas MD Anderson Cancer Center to continue critical pancreatic cancer research.

June 26, 2026

Vol.52 No.25

MD Anderson, Sibylla Biotech collaborate to develop small-molecule protein degraders

YOU MAY BE INTERESTED IN

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

Pour a Scotch, we’re talking clinical trials and prediction markets

House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role

FDA halts public release of Complete Response Letters, following citizen petition

Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

Renew today!

Subscriber content

Never miss an issue!

Login

MD Anderson, Sibylla Biotech collaborate to develop small-molecule protein degraders

YOU MAY BE INTERESTED IN

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and whyDrug development must convene a forum for candid, cross-sector discussion

Pour a Scotch, we’re talking clinical trials and prediction markets

House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role

FDA halts public release of Complete Response Letters, following citizen petition

Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

Never miss an issue!

Login

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion